BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 8952859)

  • 21. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
    Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
    Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.
    De Stefano V; Carobbio A; Di Lazzaro V; Guglielmelli P; Iurlo A; Finazzi MC; Rumi E; Cervantes F; Elli EM; Randi ML; Griesshammer M; Palandri F; Bonifacio M; Hernandez-Boluda JC; Cacciola R; Miroslava P; Carli G; Beggiato E; Ellis MH; Musolino C; Gaidano G; Rapezzi D; Tieghi A; Lunghi F; Loscocco GG; Cattaneo D; Cortelezzi A; Betti S; Rossi E; Finazzi G; Censori B; Cazzola M; Bellini M; Arellano-Rodrigo E; Bertozzi I; Sadjadian P; Vianelli N; Scaffidi L; Gomez M; Cacciola E; Vannucchi AM; Barbui T
    Blood Cancer J; 2018 Feb; 8(3):25. PubMed ID: 29535299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.
    Alvarez-Larrán A; Pereira A; Guglielmelli P; Hernández-Boluda JC; Arellano-Rodrigo E; Ferrer-Marín F; Samah A; Griesshammer M; Kerguelen A; Andreasson B; Burgaleta C; Schwarz J; García-Gutiérrez V; Ayala R; Barba P; Gómez-Casares MT; Paoli C; Drexler B; Zweegman S; McMullin MF; Samuelsson J; Harrison C; Cervantes F; Vannucchi AM; Besses C
    Haematologica; 2016 Aug; 101(8):926-31. PubMed ID: 27175028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of patients with essential thrombocythemia: current concepts and perspectives.
    Briere J; Guilmin F
    Pathol Biol (Paris); 2001 Mar; 49(2):178-83. PubMed ID: 11317966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia.
    Radaelli F; Colombi M; Calori R; Zilioli VR; Bramanti S; Iurlo A; Zanella A
    Hematol Oncol; 2007 Sep; 25(3):115-20. PubMed ID: 17464935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Essential thrombocythemia.
    Brière JB
    Orphanet J Rare Dis; 2007 Jan; 2():3. PubMed ID: 17210076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
    Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
    Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
    Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
    Landolfi R; Di Gennaro L; Novarese L; Patrono C
    Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is ticlopidine a safe alternative to aspirin for management of myeloproliferative disorders?
    Ruggeri M; Castaman G; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):18-21. PubMed ID: 8039753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of picotamide and aspirin, combined or alone, on platelet aggregation in patients with cerebral infarction.
    D'Andrea G; Perini F; Hasselmark L; Alecci M; Cananzi AR
    Funct Neurol; 1995; 10(2):91-8. PubMed ID: 7557557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of aspirin or picotamide, an antithromboxane agent, in combination with low-intensity oral anticoagulation in patients with acute myocardial infarction: a controlled randomized pilot trial.
    Vetrano A; Milani M; Corsini G
    G Ital Cardiol; 1999 May; 29(5):524-8. PubMed ID: 10367219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases.
    Buss DH; Stuart JJ; Lipscomb GE
    Am J Hematol; 1985 Dec; 20(4):365-72. PubMed ID: 3865532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.
    Andıç N; Ünübol M; Yağcı E; Akay OM; Yavaşoğlu İ; Kadıköylü VG; Bolaman AZ
    Turk J Haematol; 2016 Sep; 33(3):187-95. PubMed ID: 27094255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is the standard treatment in essential thrombocythemia.
    Barbui T
    Int J Hematol; 2002 Aug; 76 Suppl 2():311-7. PubMed ID: 12430943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
    Landolfi R; Cipriani MC; Novarese L
    Best Pract Res Clin Haematol; 2006; 19(3):617-33. PubMed ID: 16781491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pediatric stroke among Hong Kong Chinese subjects.
    Chung B; Wong V
    Pediatrics; 2004 Aug; 114(2):e206-12. PubMed ID: 15286258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study.
    Neri Serneri GG; Coccheri S; Marubini E; Violi F;
    Eur Heart J; 2004 Oct; 25(20):1845-52. PubMed ID: 15474700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
    Squizzato A; Romualdi E; Middeldorp S
    Cochrane Database Syst Rev; 2008 Apr; (2):CD006503. PubMed ID: 18425953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.